Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12020-017-1366-6 http://scihub22266oqcxt.onion/10.1007/s12020-017-1366-6 C5573756!5573756!28795329     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocrine 2017 ; 57 (3): 474-80 Nephropedia Template TP {{tp|p=28795329|t=2017. Copeptin as a marker of an altered CRH axis in pituitary disease |pdf=|usr=}}{{28795329}} gab.com Text Copeptin as a marker of an altered CRH axis in pituitary disease JO: Endocrine http://www.kidney.de/pget.php?&tw=1&pmid=28795329 #FOAvip Background: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. Patients and methods: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. Results: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n?=?20) and failing (P2, n?=?9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p?=?0.04 for P1?+?P2) with a maximum increase in controls from 3.84?±?2.86 to 12.65?±?24.87?pmol/L at 30?min, p?<?0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53?pg/mL, p?<?0.01), copeptin did not respond (e.g., 4.35?±?5.81 vs. 5.36?±?6.79?pmol/L, at 30?min, p?=?ns). Conclusions: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone?adrenocorticotropin?cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone?vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function. Twit Text FOAVip Copeptin as a marker of an altered CRH axis in pituitary disease ????Endocrine http://www.kidney.de/pget.php?&tw=1&pmid=28795329 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28795329 #FOAvip English Wikipedia <ref>{{Cite pmid|28795329}}</ref> Copeptin as a marker of an altered CRH axis in pituitary disease #MMPMID28795329 Lewandowski KC; Lewi?ski A; Skowro?ska-Jó?wiak E; Malicka K; Horzelski W; Brabant G Endocrine 2017[]; 57 (3): 474-80 PMID28795329show ga Background: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. Patients and methods: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. Results: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n?=?20) and failing (P2, n?=?9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p?=?0.04 for P1?+?P2) with a maximum increase in controls from 3.84?±?2.86 to 12.65?±?24.87?pmol/L at 30?min, p? äCopeptin as a marker of an altered CRH axis in pituitary disease (epmc).pdf DeepDyve Pubget Overpricing